Abstract
Forty consecutive patients with HD were treated with ABVD or EBVD (doxorubicin 25 mg/m2 or 4-epi-doxorubicin 37.5 mg/m2, bleomycin 10 mg/m2, vinblastine 6 mg/m2 and dacarbazine 375 mg/m2 day 1 and 14 every 28 days). Patients (pts) obtaining a complete remission (CR) after 4 cycles received up to 8 cycles, and pts obtaining a partial remission (PR) received up to 10 cycles. Two pts did not respond after 4 cycles and received a second line regimen. Twenty-two pts were male and 18 female. Median age was 36 years (13_77). 56% had nodular sclerosis, 19% mixed cellularity, 14% lymphocyte depletion and 11% lymphocyte predominance. Staging showed IE-A to III-A: 20 pts, III-B to IV-A, B: 20 pts. 12 received ABVD or EBVD after radiotherapy (RT) failure. With 4 cycles of CT 75% of pts achieved a CR (67% ABVD, 82% EBVD), this rate was increased to 95% (89% ABVD, 100% EBVD) after 8 or 10 cycles. With a median follow-up of 81 m (21_141) the freedom for progression (FFP) survival at 12 years is 86%. ABVD (or EBVD) is as or perhaps more effective and less toxic than MOPP as first line therapy in HD. In our series previous RT did not influence the results.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.